| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 浙江佐力药业股份有限公司主要从事药品的研发、生产和销售的医药制造综合性企业,公司主要产品乌灵菌粉和乌灵胶囊为现代中药行业分类之创新中药的药用真菌药类别,其核心技术特征是运用生物技术来制备现代中药.公司通过多年的研发、改进,实现了珍稀中药材-乌灵参的产业化生产,实现了传统中药材和现代生物技术应用的结合,填补了中药材领域的空白。 | ||||||||||||||||||||||||
| Main Business | 药品的研发、生产和销售 | ||||||||||||||||||||||||
| Legal Representative | 汪涛 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 冯国富 | ||||||||||||||||||||||||
| Solicitors | 上海东方华银律师事务所 | ||||||||||||||||||||||||
| Auditors | 中汇会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0572-8281383 | ||||||||||||||||||||||||
| Fax No | 0572-8281246 | ||||||||||||||||||||||||
| Website | www.zuoli.com，www.jolly.com.cn | ||||||||||||||||||||||||
| zuoli@jolly.sina.net | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 22/02/2011 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.550 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.450 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.890 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 9.930B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |